生物
癌症研究
CCL5
趋化因子
细胞生物学
细胞毒性T细胞
趋化因子受体
肿瘤微环境
焦点粘着
CD8型
免疫系统
T细胞
信号转导
免疫学
白细胞介素2受体
生物化学
体外
作者
Alan Serrels,Tom Lund,Bryan Serrels,Adam Byron,Rhoanne C. McPherson,Alex von Kriegsheim,Laura Gómez-Cuadrado,Marta Canel,Morwenna Muir,Jennifer E. Ring,Eleni Maniati,Andrew H. Sims,Jonathan A. Pachter,Valerie G. Brunton,Nick Gilbert,Stephen M. Anderton,Robert J. B. Nibbs,Margaret C. Frame
出处
期刊:Cell
[Cell Press]
日期:2015-09-01
卷期号:163 (1): 160-173
被引量:439
标识
DOI:10.1016/j.cell.2015.09.001
摘要
Focal adhesion kinase (FAK) promotes anti-tumor immune evasion. Specifically, the kinase activity of nuclear-targeted FAK in squamous cell carcinoma (SCC) cells drives exhaustion of CD8(+) T cells and recruitment of regulatory T cells (Tregs) in the tumor microenvironment by regulating chemokine/cytokine and ligand-receptor networks, including via transcription of Ccl5, which is crucial. These changes inhibit antigen-primed cytotoxic CD8(+) T cell activity, permitting growth of FAK-expressing tumors. Mechanistically, nuclear FAK is associated with chromatin and exists in complex with transcription factors and their upstream regulators that control Ccl5 expression. Furthermore, FAK's immuno-modulatory nuclear activities may be specific to cancerous squamous epithelial cells, as normal keratinocytes do not have nuclear FAK. Finally, we show that a small-molecule FAK kinase inhibitor, VS-4718, which is currently in clinical development, also drives depletion of Tregs and promotes a CD8(+) T cell-mediated anti-tumor response. Therefore, FAK inhibitors may trigger immune-mediated tumor regression, providing previously unrecognized therapeutic opportunities.
科研通智能强力驱动
Strongly Powered by AbleSci AI